EFFECTS OF CYCLOPHOSPHAMIDE ON BLADDER AND RENAL FUNCTION IN PATIENTS WITH BREAST CANCER
Main Article Content
Abstract
Objective: To investigate the effect of Cyclophosphomid on bladder and renal function in breast
cancer patients.
Subjects and methods: Descriptive-prospective cohort study, longitudinal follow-up on 68
breast cancer patients at Thu Duc City Hospital who were treated with a regimen containing
Cyclophosphamide for 4-6 cycles.
Results: Common clinical adverse effects of Cyclophosphamide on renal and bladder function
were hypogastric pain (13.24%), hematuria (16.17%). Less common manifestations were urinary
frequency (10.29%), painful urination (8.82%), cloudy urine (5.88%) and dysuria (4.41%). In the
urine before and after treatment with Cyclophosphamide, there was a change in Microalbumin
(from 5.24±0.64 to 16.21±2.01mg/dl). The results of cystoscopy showed that 19.05% of patients
had lesions. In which, 14.29% of bladder mucosal inflammation, 4.76% had ulceration and necrosis,
there was not a bladder atrophy case. The rate of patients with bladder toxicity was 13.2%, the rate
of patients without bladder toxicity was 86.8%.
Conclusion: Common clinical side effects of Cyclophosphamide on renal and bladder function
were hypogastric pain, hematuria. In the urine before and after treatment with Cyclophosphamide
there was a change in Microalbumin. Cystoscopy showed 14.29% of bladder mucosal inflammation,
4.76% had ulceration and necrosis. The proportion of patients with bladder toxicity was 13.2%.
Article Details
Keywords
Cyclophosphamide, bladder and renal function, breast cancer.
References
statistics, 2013. CA Cancer J Clin, 63(1): 11-30,
2013.
[2] Cserni G, The new TNM-based staging of breast
cancer. Virchows Arch, 472(5): 697-703, 2018.
[3] Ferlay J, Cancer incidence and mortality
worldwide: sources, methods and major patterns
in GLOBOCAN 2012. International journal of
cancer, 136(5): E359-E386, 2015.
[4] Khokher S, Clinicopathologic profile of breast
cancer patients in Pakistan: ten years data of a
local cancer hospital. Asian Pacific Journal of
Cancer Prevention, 13(2): 693-698, 2012.
[5] Moore MA, Cancer epidemiology in mainland
South-East Asia-past, present and future. Asian
Pac J Cancer Prev, 11(Suppl 2): 67-80, 2010.
[6] Han SJ, Prognostic significance of interactions
between ER alpha and ER beta and lymph node
status in breast cancer cases. Asian Pac J Cancer
Prev, 14(10): 6081-4, 2013.
[7] George P, Haemorrhagic cystitis and
cyclophosphamide. Lancet, 2(7314): 942, 1963.
[8] Plotz PH, Bladder complications in patients
receiving cyclophosphamide for systemic lupus
erythematosus or rheumatoid arthritis. Ann Intern
Med, 91(2): 221-3, 1979.
[9] Varma PP, Subba DB, Madhoosudanan P,
Cyclophosphamide induced haemorrhagic cystitis
(a case report). Med J Armed Forces India, 54(1):
59-60, 1998.
[10] Kaldor JM, Day NE, Kittelmann B et al.,
Bladder tumours following chemotherapy and
radiotherapy for ovarian cancer: a case-control
study. Int J Cancer, 63(1): 1-6, 1995.